Quantcast

Latest Erythropoietin Stories

2010-12-09 11:19:00

HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY.PK), a biopharmaceutical company, today announced it has been notified by the Tel Aviv Stock Exchange (TASE) that XTL will be included in the following TASE Indexes; "Yeter" Tel Aviv, "Tel Tech", and "Biomed", effective December 15, 2010. TASE shall conduct a "special trading" in XTL's shares at the end of trading on December 14, 2010. "We are very pleased that our...

2010-12-08 11:41:00

BANGALORE, India, December 8, 2010 /PRNewswire/ -- AVESTHAGEN LIMITED, a leading knowledge based life sciences company pioneering the convergence between Food, Pharma and Population Genetics, today announced the completion of manufacturing of the clinical grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to Darbepoetin alfa), which will now be moving into Clinical Trials. Inno Biologics, Malaysia's biopharma CMO has successfully developed Drug Substance batches for...

2010-12-06 03:25:00

PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score (IPSS) of low to intermediate-1 risk myelodysplastic syndrome (MDS). The presentation entitled Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog,...

2010-12-02 15:18:00

THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of...

2010-11-30 13:55:20

A drug called FG-2216 stimulates 'EPO' production -- even in patients without kidneys A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients"”possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Anemia is a major problem in patients with kidney disease. It is caused by low production of EPO, which...

2010-11-30 07:52:25

(Ivanhoe Newswire) -- The name of the drug is FG-2216, and it's designed to stimulate production of the hormone erythropoietin (EPO) in dialysis patients.  In fact, it's the world's first oral drug for the treatment of kidney disease-related anemia; it's a hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes the "master switch," which normally tells the body to produce EPO in response to low oxygen levels. Anemia, one of the more common blood disorders, is...

2010-11-23 07:00:00

EXTON, Pa., Nov. 23, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Renal Anemia in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 US CKD-ND patient charts. ChartTrends® compare what physicians self-report about disease management to what actually occurs at the patient level. This report evaluates the management of renal anemia...

2010-11-16 12:56:00

Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell. "Our research indicates when the two drugs were used at the same time, Herceptin was less effective," said study senior...

2010-11-16 06:00:00

CARLSBAD, Calif. and VANCOUVER, Canada, Nov. 16, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Xenon Pharmaceuticals Inc. announced today a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation (AI). Under the terms of the agreement, Isis will receive an undisclosed upfront payment in the form of a convertible promissory note from Xenon to discover and develop antisense drugs to the...

2010-11-10 17:30:49

Scientists are reporting development of a long-sought method with the potential for getting medication through a biological barrier that surrounds the brain, where it may limit the brain damage caused by stroke. Their approach for sneaking the nerve-protective drug erythropoietin into the brain is medicine's version of the Trojan Horse ploy straight out of ancient Greek legend. It also could help people with traumatic head injuries, Parkinson's disease, and other chronic brain disorders....


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related